Acute and subacute drug-induced movement disorders

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Burkhard, Pierre R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Acute dystonic reaction; Akathisia; Drug induced movement disorders; Dyskinesia; Neuroleptic malignant syndrome; Parkinsonism; Serotonin syndrome; Tremor

Indexed keywords

BENZATROPINE; BIPERIDEN; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; PROCYCLIDINE; RECREATIONAL DRUG; TRIHEXYPHENIDYL;

ACUTE DYSTONIC REACTION; AKATHISIA; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; HUMAN; HYPERKINESIA; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; OUTCOME ASSESSMENT; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; SEROTONIN SYNDROME; SYNDROME DELINEATION; TREMOR;

ACUTE DYSTONIC REACTION; AKATHISIA; DRUG-INDUCED MOVEMENT DISORDERS; DYSKINESIA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; SEROTONIN SYNDROME; TREMOR;

BASAL GANGLIA; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; MOVEMENT DISORDERS; NEUROTRANSMITTER AGENTS; TIME FACTORS;

EID: 84887946528     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70027-0     Document Type: Article

References (30)

1. Ayd FJ A survey of drug-induced extrapyramidal reactions. JAMA 1961, 175:1054-1060.
2. North RR Drug-induced movement disorders. Postgrad Med 1971, 50:180-185.
3. Gilbert DL Drug-induced movement disorders in children. Ann N Y Acad Sci 2008, 1142:72-84.
4. Robottom BJ, Shulman LM, Weiner WJ Drug-induced movement disorders: emergencies and management. Neurol Clin 2012, 30:309-320.
5. Rodnitzky RL Drug-induced movement disorders. Clin Neuropharmacol 2002, 25:142-152.
6. Dressler D, Benecke R Diagnosis and management of acute movement disorders. J Neurol 2005, 252:1299-1306.
7. Kirkham FJ, Haywood P, Kashyape P, Borbone J, Lording A, Pryde K, et al. Movement disorder emergencies in childhood. Eur J Paediatr Neurol 2011, 15:390-404.
8. Robottom BJ, Factor SA, Weiner WJ Movement disorders emergencies. Part 2: hyperkinetic disorders. Arch Neurol 2011, 68:719-724.
9. Robottom BJ, Weiner WJ, Factor SA Movement disorders emergencies. Part 1: hypokinetic disorders. Arch Neurol 2011, 68:567-572.
10. Cunningham Owens DG A guide to the extrapyramidal side-effects of antipsychotic drugs 1999, 351. Cambridge University Press, Cambridge.
11. Pierre JM Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005, 28:191-208.
12. Iselin-Chaves IA, Grotzsch H, Besson M, Burkhard PR, Savoldelli GL Naloxone-responsive acute dystonia and parkinsonism following general anaesthesia. Anaesthesia 2009, 64:1359-1362.
13. Flaherty JA, Lahmeyer HW Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment. Am J Psychiatry 1978, 135:1414-1415.
14. Marion MH, Klap P, Perrin A, Cohen M Stridor and focal laryngeal dystonia. Lancet 1992, 339:457-458.
15. Schneider SA, Udani V, Sankhla CS, Bhatia KP Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs. Mov Disord 2009, 24:1226-1229.
16. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção-Talbott S Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009, 70:627-643.
17. Lopez-Sendon J, Mena MA, de Yebenes JG Drug-induced parkinsonism. Expert Opin Drug Saf 2013, 12:487-496.
18. Trollor JN, Chen X, Chitty K, Sachdev PS Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 2012, 201:52-56.
19. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011, 72:1222-1228.
20. Gurrera RJ, Velamoor V, Cernovsky ZZ A validation study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol 2013 Aug 22, [Epub ahead of print].
21. Perry PJ, Wilborn CA Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 2012, 24:155-162.
22. Boyer EW, Shannon M The serotonin syndrome. N Engl J Med 2005, 352:1112-1120.
23. Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord 2009, 15(Suppl 3):S233-S236.
24. Urasaki E, Fukudome T, Hirose M, Nakane S, Matsuo H, et al. Neuroleptic malignant syndrome (parkinsonism-hyperpyrexia syndrome) after deep brain stimulation of the subthalamic nucleus. J Clin Neurosci 2013, 20:740-741.
25. Onofrj M, Thomas A Acute akinesia in Parkinson disease. Neurology 2005, 64:1162-1169.
26. Morgan JC, Sethi KD Drug-induced tremors. Lancet Neurol 2005, 4:866-876.
27. Zesiewicz TA, Sullivan KL Drug-induced hyperkinetic movement disorders by nonneuroleptic agents. Handb Clin Neurol 2011, 100:347-363.
28. Deik A, Saunders-Pullman R, Luciano MS Substance abuse and movement disorders: complex interactions and comorbidities. Curr Drug Abuse Rev 2012, 5:243-253.
29. Brust JC Substance abuse and movement disorders. Mov Disord 2010, 25:2010-2020.
30. Carroll I, Heritier Barras AC, Dirren E, Burkhard PR, Horvath J Delayed leuko-encephalopathy after alprazolam and methadone overdose: a case report and review of the literature. Clin Neurol Neurosurg 2012, 114:816-819.